Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27132762 | 0.98 | CYP2B6 (0.34) | CYP2B6 | |
| SCHEMBL5399745 | 0.82 | — | — | |
| SCHEMBL30722323 | 0.81 | CYP2B6 (0.31) | CYP2B6 | |
| SCHEMBL6228282 | 0.78 | — | — | |
| SCHEMBL9007363 | 0.76 | TP53 (0.35) | — | |
| SCHEMBL6914342 | 0.69 | — | — | |
| SCHEMBL6241228 | 0.69 | PPARG (0.31) | — | |
| SCHEMBL8520815 | 0.68 | MEN1 (0.31) | — | |
| SCHEMBL2847948 | 0.68 | CYP2B6 (0.31) | CYP2B6 | |
| SCHEMBL27636033 | 0.68 | KDM4E (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6162615-A | Stabilized coenzyme solutions and their use thereof for the determination of dehydrogenases or the substrate thereof in an alkaline medium | ROCHE DIAGNOSTICS GMBH (DE) | 2000-12-19 | — | — | US | claimed |
| US-8741600-B2 | Method for separation of immunoglobulin monomers | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2014-06-03 | — | — | US | disclosed |
| US-20100190965-A1 | METHOD FOR SEPARATION OF IMMUNOGLOBULIN MONOMERS | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2010-07-29 | — | — | US | disclosed |
| WO-2007149343-A2 | PROTEASES FOR TREATMENT OF VENOMOUS BITES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2007-12-27 | — | — | WO | disclosed |
| US-7101621-B2 | Azlactone-functional hydrophilic coatings and hydrogels | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-09-05 | — | — | US | disclosed |
| US-20050003198-A1 | Azlactone-functional hydrophilic coatings and hydrogels | 3M INNOVATIVE PROPERTIES COMPANY | 2005-01-06 | — | — | US | disclosed |
| US-6794458-B2 | IMMOBILIZATION OF DNA, PROTEIN | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-21 | — | — | US | disclosed |
| EP-1387857-A1 | AZLACTONE-FUNCTIONAL HYDROPHILIC COATINGS AND HYDROGELS | 3M Innovative Properties Company (US) | 2004-02-11 | — | — | EP | disclosed |
| US-6537823-B1 | Use in determination of adulterants in illicit drug screening samples as a means of detecting false negative results | SCITECK DIAGNOSTICS, INC. | 2003-03-25 | — | — | US | disclosed |
| US-20030049435-A1 | Azlactone-functional hydrophilic coatings and hydrogels | 3M INNOVATIVE PROPERTIES COMPANY | 2003-03-13 | — | — | US | disclosed |
| WO-2002094890-A1 | AZLACTONE-FUNCTIONAL HYDROPHILIC COATINGS AND HYDROGELS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-11-28 | — | — | WO | disclosed |
| EP-0775215-B1 | CHEMILUMINESCENCE ASSAYS BASED ON INDOXYL SUBSTRATES OR THIOINDOXYL SUBSTRATES | MEDILITE DIAGNOSTIKA (US) | 2001-12-19 | — | — | EP | disclosed |
| US-5814623-A | USEFUL IN TREATMENT OF HYPERTENSION, HEART DISEASE, AND RENAL DISEASE | ACADEMIC PHARMACEUTICALS, L.P. (US) | 1998-09-29 | — | — | US | disclosed |
| EP-0775215-A1 | CHEMILUMINESCENCE ASSAYS BASED ON INDOXYL SUBSTRATES, THIOINDOXYL SUBSTRATES AND OTHER SUBSTRATES | MEDILITE DIAGNOSTIKA (US) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996004400-A1 | CHEMILUMINESCENCE ASSAYS BASED ON INDOXYL SUBSTRATES, THIOINDOXYL SUBSTRATES AND OTHER SUBSTRATES | MEDILITE DIAGNOSTIKA (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190965-A1 | METHOD FOR SEPARATION OF IMMUNOGLOBULIN MONOMERS | IGLV6-57, FCGR1A, FCGR2A | CYP2B6 3939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.